HK1258803A1 - 賴諾普利製劑 - Google Patents

賴諾普利製劑

Info

Publication number
HK1258803A1
HK1258803A1 HK19101168.3A HK19101168A HK1258803A1 HK 1258803 A1 HK1258803 A1 HK 1258803A1 HK 19101168 A HK19101168 A HK 19101168A HK 1258803 A1 HK1258803 A1 HK 1258803A1
Authority
HK
Hong Kong
Prior art keywords
lisinopril formulations
lisinopril
formulations
Prior art date
Application number
HK19101168.3A
Other languages
English (en)
Inventor
Gerold L Mosher
David W Miles
Original Assignee
Silvergate Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57046225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1258803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silvergate Pharmaceuticals Inc filed Critical Silvergate Pharmaceuticals Inc
Publication of HK1258803A1 publication Critical patent/HK1258803A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK19101168.3A 2015-10-30 2019-01-23 賴諾普利製劑 HK1258803A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562249011P 2015-10-30 2015-10-30
US14/934,752 US9463183B1 (en) 2015-10-30 2015-11-06 Lisinopril formulations
PCT/US2016/059348 WO2017075368A1 (en) 2015-10-30 2016-10-28 Lisinopril formulations

Publications (1)

Publication Number Publication Date
HK1258803A1 true HK1258803A1 (zh) 2019-11-22

Family

ID=57046225

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101168.3A HK1258803A1 (zh) 2015-10-30 2019-01-23 賴諾普利製劑

Country Status (9)

Country Link
US (11) US9463183B1 (zh)
EP (2) EP3368012B1 (zh)
JP (1) JP2018533583A (zh)
KR (1) KR20180069907A (zh)
CN (2) CN112972370A (zh)
CA (1) CA3003274A1 (zh)
ES (1) ES2886869T3 (zh)
HK (1) HK1258803A1 (zh)
WO (1) WO2017075368A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) * 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CA3061479A1 (en) 2017-04-25 2018-11-01 Proteus Digital Health, Inc. Lisinopril compositions with an ingestible event marker
WO2018204040A1 (en) * 2017-05-01 2018-11-08 Bioramo, Llc Oral liquid compositions of valsartan
CN108939045A (zh) * 2017-05-25 2018-12-07 北京万全德众医药生物技术有限公司 一种赖诺普利口服溶液及其制备方法
US11612566B2 (en) 2019-05-29 2023-03-28 OWP Pharmaceuticals, Inc. Lamotrigine oral liquid suspension and use thereof
US11596634B2 (en) * 2019-05-29 2023-03-07 OWP Pharmaceuticals, Inc. Lamotrigine oral liquid suspension and use thereof
CN113143863A (zh) * 2020-01-22 2021-07-23 浙江贝灵生物医药有限公司 一种口服溶媒组合物及其制备方法与应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003980A (en) 1909-03-20 1911-09-26 Charles Henry Bull Car-seal.
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
CA1275350C (en) 1978-12-11 1990-10-16 Edward W. Tristram Lisinopril
US4510083A (en) 1982-05-07 1985-04-09 Merck & Co., Inc. Process for preparing polypeptides
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4931430A (en) 1987-12-14 1990-06-05 E. R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing an ACE inhibitor
US5049553A (en) 1990-01-04 1991-09-17 E. R. Squibb & Sons, Inc. Method for preventing or treating symptoms resulting from closed head injuries employing an ace inhibitor
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
US5698562A (en) 1991-10-08 1997-12-16 Ascent Pediatrics, Inc. Palatable trimethoprim oral solution
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
BR9712197A (pt) 1996-10-04 1999-08-31 Merck & Co Inc Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.
TW592709B (en) 1999-04-29 2004-06-21 Janssen Pharmaceutica Nv Prucalopride oral solution
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
SI20411A (sl) 1999-12-22 2001-06-30 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Vodotopni praški za peroralno raztopino in njihova uporaba
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
FR2824477B1 (fr) 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
AU2003261167A1 (en) 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
CA2496806A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Oral liquid tolterodine composition
US6869963B2 (en) 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
WO2005070390A2 (en) 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
US20060094760A1 (en) 2004-11-04 2006-05-04 Fawzy Abdel A Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
US8153824B2 (en) 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
EP1978933A2 (en) 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
WO2007142707A1 (en) 2006-02-06 2007-12-13 Pharmaceutical Solutions, Inc. Non-steroidal anti-inflammatory oral powder and liquid preparations for administration to animals
WO2007128060A1 (en) * 2006-05-05 2007-11-15 Bt Imaging Pty Ltd Method and system for testing indirect bandgap semiconductor devices using luminescence imaging
US7605148B2 (en) 2007-04-16 2009-10-20 Aurobindo Pharma Ltd. Aqueous oral solution of bisphosphonic acid
JP2011500577A (ja) * 2007-10-09 2011-01-06 ノバルティス アーゲー バルサルタンの医薬製剤
TW200938542A (en) * 2008-02-01 2009-09-16 Irm Llc Compounds and compositions as kinase inhibitors
EP2265253A2 (en) * 2008-02-19 2010-12-29 Marvel Lifesciences Limited Oral dosage form containing a pyridinol derivative
RU2010139833A (ru) * 2008-04-28 2012-06-10 Дзе Проктер Энд Гэмбл Компани (US) Композиции для ухода за полостью рта
US8877746B2 (en) 2009-08-25 2014-11-04 Cardioklne, Inc Compositions for delivery of insoluble agents
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
EA023996B1 (ru) 2010-12-24 2016-08-31 КРКА, д.д., НОВО МЕСТО Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацевтически приемлемые соли совместно с органической кислотой
SG10201609364QA (en) 2012-05-18 2017-01-27 Luoda Pharma Pty Ltd Liquid formulation
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US9463183B1 (en) * 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
JP2017224942A (ja) 2016-06-14 2017-12-21 フォーブ インコーポレーテッド ヘッドマウントディスプレイ、視線検出システム

Also Published As

Publication number Publication date
JP2018533583A (ja) 2018-11-15
US11771733B2 (en) 2023-10-03
US9814751B2 (en) 2017-11-14
EP3368012A4 (en) 2019-06-05
US11179434B2 (en) 2021-11-23
EP3368012A1 (en) 2018-09-05
CN108472252B (zh) 2021-01-26
US10940177B2 (en) 2021-03-09
KR20180069907A (ko) 2018-06-25
US9616096B1 (en) 2017-04-11
WO2017075368A1 (en) 2017-05-04
ES2886869T3 (es) 2021-12-21
US20200237851A1 (en) 2020-07-30
US20180078604A1 (en) 2018-03-22
CA3003274A1 (en) 2017-05-04
US20170119840A1 (en) 2017-05-04
US9463183B1 (en) 2016-10-11
EP3960156A1 (en) 2022-03-02
US20220111000A1 (en) 2022-04-14
US20190201475A1 (en) 2019-07-04
US10039800B2 (en) 2018-08-07
US10265370B2 (en) 2019-04-23
CN108472252A (zh) 2018-08-31
CN112972370A (zh) 2021-06-18
US10406199B2 (en) 2019-09-10
EP3368012B1 (en) 2021-08-11
US20200206298A1 (en) 2020-07-02
US20210187055A1 (en) 2021-06-24
US20170209523A1 (en) 2017-07-27
US20180339011A1 (en) 2018-11-29
US20230405079A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL268697A (en) Formulations
IL269630A (en) Niraprib formulations
IL269621A (en) Niraparib formulations
HK1258803A1 (zh) 賴諾普利製劑
SG10201607915YA (en) Cleaning formulations
IL265609A (en) New formulations
IL273282A (en) Niraprib formulations
SI4070788T1 (sl) Farmacevtske formulacije
GB201607918D0 (en) Novel formulations
HK1254343A1 (zh) 藥物製劑
SG11201707787SA (en) Cleaning formulations
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
HK1254980A1 (zh) 混合配方
ZA201707094B (en) Pharmaceutical formulations
GB201714461D0 (en) Formulations
GB201621277D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201617866D0 (en) Novel formulations
GB201616509D0 (en) Novel formulations
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations